Westlake BioPartners | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Westlake BioPartners/Activity

Westlake BioPartners Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Team Change

Appointed Mira Chaurushiya, Ph.D. as Senior Partner.

Mira Chaurushiya appointed Senior Partner

Westlake BioPartners

westlakebio.com

Added recently

Investment

Co-led Vedana Therapeutics' $46M Series A financing to advance next-generation migraine prevention therapies.

Vedana Therapeutics

Vedana Therapeutics Westlake BioPartners

businesswire.comJUN 17, 2026

westlakebio.com

JUN 17, 2026

Investment

Co-led AllRock Bio's $50M Series A with Versant Ventures to advance ROC-101 for pulmonary arterial hypertension.

AllRock Bio

AllRock Bio Westlake BioPartners

prnewswire.comSEP 16, 2025

westlakebio.com

SEP 16, 2025

Exit

Portfolio company ACELYRIN merged with Alumis Inc. to form a late-stage clinical immunology biopharma company.

Acelyrin

Acelyrin Westlake BioPartners

investors.alumis.comMAY 2025

MAY 2025

Exit

Portfolio company Kate Therapeutics was acquired by Novartis for up to $1.1B including milestones.

Kate Therapeutics

Kate Therapeutics Westlake BioPartners

statnews.comNOV 2024

NOV 2024

New Fund

Closed $450M Fund III and appointed David Allison as Managing Director, bringing total capital raised since 2018 to $1.3B.

Fund III ($450M)

Westlake BioPartners

prnewswire.comJUL 2023

JUL 2023